]>
IRCT20210326050772N1 IRCT 2021-09-13 Zanjan University of Medical Sciences Evaluation of the efficacy of Selenium supplementation therapy on the inflammatory markers oxidative stress and liver functional parameters Evaluation of the efficacy of Selenium supplementation therapy on the inflammatory markers oxidative stress and liver functional parameters in thalassemia major and intermediate 2021-09-22 anticipated 40 Complete https://irct.ir/trial/55675 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Supportive. 2 Thalassemia major and intermedia. In these patients, in addition to routine treatments, they will take 200 micrograms of selenium tablets daily for 30 days.. Yes - There is a plan to make this available What will be shared: After completing the study, there is a plan to share non-identifiable individual data of the participants, the study protocol, the statistical analysis of the data, the informed consent form patents, clinical reports, analysis codes, and data coding systems (Dictionary). When: The start of the access period to the data of this study will be from Early 2022 and approximately 6 months after the publication of the results. To whom: The data of this study are possible for all patients with thalassemia major and intermedia, and especially those working in health care systems. Conditions: The researcher wants to use the data to improve major and intermedia Thalassemia. Where to obtain: To receive information anyone can be use the following email: Kddavari@zums.ac.ir, soltanpoorm@zums.ac.ir How to obtain: After sending the message and introducing herself or himself and the reason for the need for data, the applicant will be provided with the information after confirmation. Comments:
public Dr.Kambiz Davari
Ayatollah Mousavi Hospital, Gavazang Street,Pro. Soboti Blv, Zanjan, Iran
Zanjan Iran (Islamic Republic of) 4513956183 +98 24 3313 0000 Kddavari@zums.ac.ir Zanjan University of Medical Sciences scientific Dr.kambiz Davari
Ayatollah Mousavi hospital, Gavazang Street, Pro. Soboti Blv, Zanjan, Iran
Zanjan Iran (Islamic Republic of) 4513956183 +98 24 3313 0000 Kddavari@zums.ac.ir Zanjan University of Medical Sciences Iran (Islamic Republic of) Willingness to participate in the study Having thalassemia major or intermedia Having healthy liver and kidney function no limit no limit Both History of chemotherapy Take any supplements and vitamins at least two months before the study Diabetic patients Patients with acute and chronic infections Having any inflammatory disease D56.1 Beta thalassemia Other In these patients, in addition to routine treatments, they will take 200 micrograms of selenium tablets daily for 30 days. Inflammatory markers. Timepoint: Before the intervention and 30 days after the start of selenium consumption. Method of measurement: By measuring the inflammatory markers hCRP and ferritin. Oxidative stress marker (Malondialdehyde). Timepoint: Before the intervention and 30 days after the start of selenium consumption. Method of measurement: By measuring the oxidative stress markers (Malondialdehyde). Liver function parameters. Timepoint: Before the intervention and 30 days after the start of selenium consumption. Method of measurement: By measuring the liver function parameters (AST and ALT). Zanjan University of Medical Sciences Approved 2020-10-13 Ethics Committee of Deputy of Research and Technology of Zanjan University of Medical Sciences Deputy of Research and Technology, third floor, Second building, Central Headquarters of Zanjan University of Medical Sciences, The beginning of Jomhuri Eslami Boulevard, Azadi Blv, Zanjan, Iran Zanjan Zanjan Iran (Islamic Republic of)